195 related articles for article (PubMed ID: 34925245)
1. Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria.
Liu X; Xu J; Bi L; Liu P; Jiao X
Front Endocrinol (Lausanne); 2021; 12():790160. PubMed ID: 34925245
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors for Live Birth in Fresh
Li F; Ye T; Kong H; Li J; Hu L; Jin H; Guo Y; Li G
Front Endocrinol (Lausanne); 2021; 12():630832. PubMed ID: 33967954
[TBL] [Abstract][Full Text] [Related]
3. Cumulative live birth rates in low-prognosis women.
Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
[TBL] [Abstract][Full Text] [Related]
4. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis.
Du M; Zhang J; Li Z; Liu X; Li J; Liu W; Guan Y
Front Endocrinol (Lausanne); 2021; 12():705264. PubMed ID: 34589055
[TBL] [Abstract][Full Text] [Related]
6. Live birth rate per fresh embryo transfer and cumulative live birth rate in patients with PCOS under the POSEIDON classification: a retrospective study.
Jiang L; Sun Y; Pan P; Li L; Yang D; Huang J; Li Y
Front Endocrinol (Lausanne); 2024; 15():1348771. PubMed ID: 38863934
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial.
Xu Y; Nisenblat V; Lu C; Li R; Qiao J; Zhen X; Wang S
Reprod Biol Endocrinol; 2018 Mar; 16(1):29. PubMed ID: 29587861
[TBL] [Abstract][Full Text] [Related]
8. The effect of growth hormone supplementation in poor ovarian responders undergoing IVF or ICSI: a meta-analysis of randomized controlled trials.
Yang P; Wu R; Zhang H
Reprod Biol Endocrinol; 2020 Jul; 18(1):76. PubMed ID: 32727608
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study.
Zhang S; Yin Y; Li Q; Zhang C
Front Endocrinol (Lausanne); 2021; 12():644456. PubMed ID: 34234739
[TBL] [Abstract][Full Text] [Related]
10. The role of intracytoplasmic sperm injection in non-male factor infertility in advanced maternal age.
Tannus S; Son WY; Gilman A; Younes G; Shavit T; Dahan MH
Hum Reprod; 2017 Jan; 32(1):119-124. PubMed ID: 27852688
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone cotreatment for poor responders undergoing in vitro fertilization cycles: a systematic review and meta-analysis.
Cozzolino M; Cecchino GN; Troiano G; Romanelli C
Fertil Steril; 2020 Jul; 114(1):97-109. PubMed ID: 32553470
[TBL] [Abstract][Full Text] [Related]
12. Does growth hormone supplementation of in vitro fertilization/intracytoplasmic sperm injection improve cumulative live birth rates in women with poor embryonic development in the previous cycle?
Liu X; Li N; Wang D; Wen W; Tian L; Zhou H; Mol BW; Shi J; Wang T
Reprod Biol Endocrinol; 2024 May; 22(1):53. PubMed ID: 38715065
[TBL] [Abstract][Full Text] [Related]
13. Management Strategies for POSEIDON Group 2.
Sunkara SK; Ramaraju GA; Kamath MS
Front Endocrinol (Lausanne); 2020; 11():105. PubMed ID: 32174892
[TBL] [Abstract][Full Text] [Related]
14. Maternal and neonatal complications after IVF/ICSI-fresh embryo transfer in low-prognosis women under the POSEIDON criteria: a retrospective cohort study.
Li S; Tan H; Fu H; Du J; Liu P; Qin Y
BMC Pregnancy Childbirth; 2023 Dec; 23(1):855. PubMed ID: 38087253
[TBL] [Abstract][Full Text] [Related]
15. Prediction of pregnancy outcome in fresh
Chen Y; Niu A; Feng X; Zhang Y; Li F
Aging (Albany NY); 2021 Jul; 13(14):18331-18339. PubMed ID: 34273144
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial.
Gong Y; Zhang K; Xiong D; Wei J; Tan H; Qin S
Reprod Biol Endocrinol; 2020 Sep; 18(1):91. PubMed ID: 32891163
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone supplementation during ovarian stimulation improves oocyte and embryo outcomes in IVF/PGT-A cycles of women who are not poor responders.
Skillern A; Leonard W; Pike J; Mak W
J Assist Reprod Genet; 2021 May; 38(5):1055-1060. PubMed ID: 33534048
[TBL] [Abstract][Full Text] [Related]
18. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
[TBL] [Abstract][Full Text] [Related]
19. Follicular Output Rate and Follicle-to-Oocyte Index of Low Prognosis Patients According to POSEIDON Criteria: A Retrospective Cohort Study of 32,128 Treatment Cycles.
Chen L; Wang H; Zhou H; Bai H; Wang T; Shi W; Shi J
Front Endocrinol (Lausanne); 2020; 11():181. PubMed ID: 32318023
[TBL] [Abstract][Full Text] [Related]
20. Analysis of IVF/ICSI-FET Outcomes in Women With Advanced Endometriosis: Influence on Ovarian Response and Oocyte Competence.
Li A; Zhang J; Kuang Y; Yu C
Front Endocrinol (Lausanne); 2020; 11():427. PubMed ID: 32765424
[No Abstract] [Full Text] [Related]
[Next] [New Search]
